Handa Pharmaceuticals (ROCO:6620) Total Equity: NT$5,023 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
86 GF Score
Price NT$107.50
GF Value NT$109.77
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Handa Pharmaceuticals Total Equity?

Handa Pharmaceuticals ROCO:6620 +9.69% 86 Total Equity is NT$5,023 Mil as of Jun. 2026. GuruFocus rates ROCO:6620 with a GF Score™ of 86/100 and a GF Value™ of NT$109.77 (Fairly Valued). The stock has 4 warning signs investors should review.

Handa Pharmaceuticals's total equity for the quarter that ended in Jun. 2026 was NT$5,023 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Handa Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Handa Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Handa Pharmaceuticals Total Equity Chart

Handa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 463.10 721.12 2,756.31 3,117.32 5,660.46

Handa Pharmaceuticals Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,224.49 4,489.77 5,660.46 5,287.93 5,022.95
ROCO:6620
86GF Score
Handa Pharmaceuticals Inc ROCO:6620
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Handa Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Handa Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=5892.512-232.053
=5,660

Handa Pharmaceuticals's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=5580.856-557.908
=5,023

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$5,023 Mil mean?
Handa Pharmaceuticals (ROCO:6620) has a Total Equity of NT$5,023 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Handa Pharmaceuticals and its competitors.
Is Handa Pharmaceuticals' Total Equity too high?
Handa Pharmaceuticals' current Total Equity is NT$5,023 Mil. Overall, Handa Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' Total Equity compare to ZTS?
Handa Pharmaceuticals' Total Equity of NT$5,023 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Handa Pharmaceuticals and its competitors. Handa Pharmaceuticals's current Total Equity is NT$5,023 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Fairly Valued. The stock's GF Value™ is NT$109.77, compared to a current price of NT$107.50 — trading 2.1% below its estimated fair value. The current Total Equity is NT$5,023 Mil. Handa Pharmaceuticals' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current Total Equity is NT$5,023 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$107.50 is trading 2.1% below its estimated GF Value™ of NT$109.77. GuruFocus considers Handa Pharmaceuticals to be Fairly Valued.

Key valuation signals for ROCO:6620:

  • Total Equity: NT$5,023 Mil
  • GF Value™: NT$109.77 vs. price of NT$107.50 (2.1% below fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
86GF Score

Get the complete analysis for ROCO:6620

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$107.50
Price
NT$109.77
GF Value